Combination therapy based on pegylated interferon alfa improves the therapeutic response of patients with chronic hepatitis B who exhibit high levels of hepatitis B e-antigen at 24 weeks: A retrospective observational study

Pegylated interferon alpha (PEG-IFN-α) is a first-line treatment for patients with chronic hepatitis B (CHB), but its efficacy varies from individual to individual. Early discrimination between responder and non-responder patients is important for optimal clinical management. In addition, low therap...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yafei, Li, Wei, Liu, Zhongping, Ye, Jun, Zou, Guizhou, Zhang, Zhenhua, Li, Jiabin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
4500
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6738969/
https://www.ncbi.nlm.nih.gov/pubmed/31490387
http://dx.doi.org/10.1097/MD.0000000000017022

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6738969/
https://www.ncbi.nlm.nih.gov/pubmed/31490387
http://dx.doi.org/10.1097/MD.0000000000017022

Ejemplares similares